Key result
Empagliflozin consistently cuts cardiorenal events and mortality in T2DM with CVD regardless of COPD status.
RCT (n=7,020)
Answers are grounded in this paper and cite their sources.
AIMS: Type 2 diabetes mellitus (T2DM) and chronic obstructive pulmonary disease (COPD) often co-exist, yielding increased risk of cardiovascular (CV) complications including heart failure (HF). We assessed risk of cardiorenal outcomes, mortality and safety in patients with versus without COPD in the EMPA-REG OUTCOME trial. METHODS: Patients (n = 7,020) with T2DM and CV disease (CVD) were treated with empagliflozin (10 mg or 25 mg) or placebo. Cox regression was used to assess COPD subgroup (placebo only) associations with, and treatment effects of empagliflozin versus placebo on first hospitalization for HF (HHF), CV death, all-cause mortality, incident/worsening nephropathy, and all-cause hospitalization. RESULTS: At baseline, patients with COPD (n = 707) had more HF and used insulin more frequently than those without COPD. During follow-up in the placebo group, those with baseline COPD had increased risk of HHF (HR 2.15 [95% CI 1.32, 3.49]), HHF/CV death (1.60 [1.10, 2.33]), incident/worsening nephropathy (1.68 [1.26, 2.24]), all-cause hospitalization (1.44 [1.19, 1.74]) and all-cause death (1.60 [1.09, 2.35]) compared to those without COPD. Empagliflozin consistently reduced all clinical outcomes, irrespective of COPD status (interaction p-values 0.14 to 0.96), with a confirmed safety profile. CONCLUSIONS: In patients with T2DM and CVD, COPD increased the risk of mortality and cardiorenal outcomes, including HF. Empagliflozin consistently reduced these outcomes versus placebo regardless of COPD, suggesting that empagliflozin's benefits in patients with T2DM and CVD are not mitigated by the presence of COPD.
No takes yet. Share an insight, caveat, or question.
Anker et al. (2022) conducted an RCT in Type 2 diabetes mellitus and cardiovascular disease (with or without chronic obstructive pulmonary disease) (n=7,020). Empagliflozin vs. Placebo was evaluated on First hospitalization for heart failure, cardiovascular death, all-cause mortality, incident/worsening nephropathy, and all-cause hospitalization (HR 2.15, 95% CI 1.32-3.49, p=interaction p-values 0.14 to 0.96). Empagliflozin consistently reduced cardiorenal outcomes and mortality in T2DM and CVD patients regardless of COPD status.
Synapse has enriched 10 related papers. Consider them for comparative context: